Cost-Effectiveness Analysis of Budesonide/Formoterol and Fluticasone/Salmeterol for Stable Chronic Obstructive Lung Disease

Background: Chronic Obstructive Pulmonary Disease (COPD) is one of the four largest types non-communicable diseases in world, requiring long-term and routine treatment. Treatment with inhalation route form a dry-powder inhaler (DPI) which easy to use carry. Combination corticosteroid long-acting beta-2 agonist (LABA) DPI available Indonesia are budesonide/formoterol salmeterol/fluticasone. The purpose was identify therapy more cost-effective between than fluticasone/salmeterol clinical symptoms using COPD assessment test (CAT) value lung function FEV1/FVC (Forced Expiratory Volume First Seconds/Forced Vital Capacity) ratio.Methods: This research study pre-post design cost-effectiveness analysis, outpatient patients hospital Gresik Regency, from October 2019 January 2020. There were two outcomes respondents this study, namely seen FEV1, CAT. used perspective.Results: 38 involved. Fluticasone/salmeterol effective group improving ratio, while by CAT assessment. average cost effectiveness ratio (ACER) (IDR.176.465/Liter) lower that (IDR.296.832/Liter). ACER (IDR.16,283/score) smaller (IDR.17,340/score). Conclusion: function. Meanwhile, for symptoms, trade-off budesonide/formoterol.